序贯SAFE评分与瞬时弹性成像检测亚洲MASLD患者显著纤维化
该研究比较SAFE、FIB-4和NFS在亚洲MASLD患者中检测显著纤维化(F≥2)的性能,并评估SAFE-TE序贯策略。研究假设先用SAFE可减少已存在F≥2但被误判为低风险的患者比例。
要点
- SAFE评分近期被开发用于预测F≥2,外部验证优于FIB-4和NFS。
- 国际指南提出先用FIB-4、非低风险者再用瞬时弹性成像的序贯步骤,但聚焦于F≥3。
- 研究旨在比较SAFE、FIB-4和NFS性能,并评估SAFE-TE序贯方法。
核心结论
- 研究假设先用SAFE可减少已存在F≥2但被误判为低风险的患者比例。
研究设计与样本
- 研究比较SAFE、FIB-4和NFS在亚洲MASLD患者中检测F≥2的性能,并评估SAFE-TE序贯方法。
临床怎么用
- 在初级保健机构中,F≥2者应转诊至肝病科医生;因此无创检测对MASLD患者风险分层至关重要。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD),1 represents a global public health issue. Fibrosis stage is the most important risk for long-term undesirable outcomes.2,3 From recent meta-analyses, all-cause and liver-related mortalities significantly increased from fibrosis stage 2 (significant fibrosis; F≥2) onward.4,5 In primary care setting, those with F≥2 should be referred to hepatologists; therefore, noninvasive tests to stratify risk of patients with MASLD are crucial. Steatosis-associated fibrosis estimator (SAFE) was recently developed to predict F≥2.6 SAFE has been externally validated and outperformed fibrosis-4 (FIB-4) and NAFLD fibrosis score (NFS).7,8 Recently, international guidelines proposed sequential diagnostic steps, initially using FIB-4 and then transient elastography (TE) in non-low-risk patients.9,10 However, the guidelines focused on identifying advanced fibrosis (F≥3), which might be too late. This study aimed to compare the performance among SAFE, FIB-4, and NFS, and evaluate SAFE-TE sequential approach. We hypothesized that by initially using SAFE, the proportion of patients misclassified as low risk despite already having F≥2 could be diminished.
引用
- Kaewdech A, Sripongpun P, Treeprasertsuk S, et al. Sequential SAFE Score and Transient Elastography for Detecting Significant Fibrosis in Asian Patients with MASLD. Clin Gastroenterol Hepatol. 2024. PMID: 38880124. doi:10.1016/j.cgh.2024.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。